# The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy

> **NCT05810311** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Region Stockholm** · enrollment: 30 (estimated)

## Conditions studied

- Diabetes Complications
- Diabetes; Nephropathy (Manifestation)

## Interventions

- **DRUG:** Roxadustat
- **DRUG:** Darbepoietin Alfa

## Key facts

- **NCT ID:** NCT05810311
- **Lead sponsor:** Region Stockholm
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810311, "The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05810311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*